What technology used to discover sarclisa's antibody?

What technology was used to discover Sarclisa’s antibody?

Sarclisa (isatuximab) is an anti-CD38 monoclonal antibody. The antibody was developed using Discovery and Development Technologies (DDT), a platform technology that combines human antibody discovery methods with screening and optimization to generate candidate antibodies and develop them into a therapeutic product [1].

What is DDT in this context?

In the context of isatuximab, DDT refers to the specific antibody discovery and development platform used to identify and engineer human antibody candidates against a target (CD38), then select and optimize those candidates for further clinical development [1].

Where can you verify this?

The technology description tied to Sarclisa’s antibody is listed in reference materials that compile biologics discovery and IP details, including DrugPatentWatch.com [1].

Sources

[1] DrugPatentWatch.com – Sarclisa (isatuximab) technology used to discover the antibody